Organisation paid for research Program year 2022 Source: CMS Open Payments

Rama Rsrch LLC

Neither a doctor nor a teaching hospital

Research payments

$463,761

557 payments

Through program year 2022, Rama Rsrch LLC is reported as receiving $463,761 in research payments, across 557 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$81	1
2021	Research	$60,097	100
2020	Research	$106,261	160
2019	Research	$297,322	296

Breakdown

Who paid Research payments · program years 2019–2022

Boehringer Ingelheim Pharma GmbH & Co.KG $241,031 65 payments
Boehringer Ingelheim International GmbH $202,463 478 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $18,953 3 payments
Boehringer Ingelheim France S.A.S. $699 5 payments
Boehringer Ingelheim Canada Ltd.Ltee $616 6 payments

Studies the money was for Research payments · program years 2019–2022

Empagliflozin and heart failure (HFpEF) $370,226 419 payments
Empagliflozin and Heart failure (HFrEF) $65,969 117 payments
GLORIA AF Registry Phase II III Core $18,810 1 payment
Exercise capacity study in HFrEF $5,362 9 payments
Exercise capacity study in HFpEF $3,313 10 payments
Empagliflozin and heart failure HFpEF $81 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.